csirt@kutim:~/threat-intel/cve/CVE-2026-80426

Katalog CVE

CVSS 7.1 · High EPSS 0,41%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting'). Skor CVSS 3.1 7.1 (High) menurut vulncheck.com.

Deskripsi (NVD)

FiftyOne renders a dataset field's description as markup. The sidebar field-information component at app/packages/core/src/components/FieldLabelAndInfo/index.tsx passes the description string to React's dangerouslySetInnerHTML, and no layer between storage and render escapes or sanitises it; the neighbouring info values in the same component are rendered as React children and are escaped, so the description is the only raw path. A description is free-form text held in the dataset schema, so it persists in the database and travels with an exported or published dataset. Opening a dataset obtained from another party and hovering the field runs the stored markup in the application's origin. That origin is shared with the FiftyOne server, whose media route returns the contents of a caller-named absolute path and which is unauthenticated in the open-source server, so the injected script can read local files and reach the dataset and operator endpoints as the viewing user.

Rincian

Terbit di NVD
26 Agustus 2026
Terakhir diubah
24 September 2026
Status NVD
Deferred
CVSS 3.1
7.1 (High), sumber vulncheck.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,41% peluang dieksploitasi; lebih tinggi dari 33,4% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.